Assignee
ASANA BIOSCIENCES LLC
US·35 granted patents·15 pending applications·57 citations·filing 2012–2024
Top patents by PatentIndex Score
50 records- 0190US11103491B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2020·Granted Aug 31, 2021·2 cites·12 claims
- 0289US11339169B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2020·Granted May 24, 2022·2 cites·39 claims
- 0389US9908879B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2016·Granted Mar 6, 2018·5 cites·43 claims
- 0486US9944637B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2014·Granted Apr 17, 2018·5 cites·30 claims
- 0586US9382277B2Pyrimido-pyridazinone compounds and methods of use thereofASANA BIOSCIENCES LLC·Filed 2014·Granted Jul 5, 2016·8 cites·28 claims
- 0685US10174039B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2017·Granted Jan 8, 2019·4 cites·39 claims
- 0785US2024391925A1P2x3 and/or p2x2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2024·Application pending·0 cites
- 0884US11434278B2Protein-polymer-drug conjugatesASANA BIOSCIENCES LLC·Filed 2019·Granted Sep 6, 2022·1 cites·4 claims
- 0984US10751332B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2016·Granted Aug 25, 2020·2 cites·7 claims
- 1083US10316039B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2018·Granted Jun 11, 2019·2 cites·3 claims
- 1182US10471051B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2017·Granted Nov 12, 2019·3 cites·38 claims
- 1282US10316080B2Protein-polymer-drug conjugatesASANA BIOSCIENCES LLC·Filed 2014·Granted Jun 11, 2019·4 cites·4 claims
- 1382US10188654B2Uses of pyrimido-pyridazinones to treat cancerASANA BIOSCIENCES LLC·Filed 2016·Granted Jan 29, 2019·3 cites·17 claims
- 1482US9896445B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2016·Granted Feb 20, 2018·3 cites·27 claims
- 1581US10611768B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2018·Granted Apr 7, 2020·2 cites·43 claims
- 1680US10647720B2Pyrimido-pyridazinone compounds and methods of use thereofASANA BIOSCIENCES LLC·Filed 2018·Granted May 12, 2020·1 cites·33 claims
- 1780US9499495B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2014·Granted Nov 22, 2016·4 cites·43 claims
- 1879US10544145B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2019·Granted Jan 28, 2020·1 cites·17 claims
- 1978US10590127B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2018·Granted Mar 17, 2020·1 cites·32 claims
- 2076US12077543B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2022·Granted Sep 3, 2024·0 cites·2 claims
- 2176US11925629B2Heterocyclic inhibitors of ERK1 and ERK2 and their use in the treatment of cancerASANA BIOSCIENCES LLC·Filed 2021·Granted Mar 12, 2024·0 cites·14 claims
- 2275US11685736B2P2X3 and/or P2X2/3 compounds and methodsASANA BIOSCIENCES LLC·Filed 2019·Granted Jun 27, 2023·0 cites·44 claims
- 2374US9044482B2Use of aminoindane compounds in treating overactive bladder and interstitial cystitisASANA BIOSCIENCES LLC·Filed 2013·Granted Jun 2, 2015·2 cites·14 claims
- 2474US2023183326A1Protein-polymer-drug conjugatesASANA BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 2572US10183944B2Pyrimido-pyridazinone compounds and methods of use thereofASANA BIOSCIENCES LLC·Filed 2016·Granted Jan 22, 2019·1 cites·26 claims
- 2672US2021113578A1Quinazolines and azaquinazolines as dual inhibitors of ras/raf/mek/erk and pi3k/akt/pten/mtor pathwaysASANA BIOSCIENCES LLC·Filed 2020·Application pending·0 cites
- 2770US10912779B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2019·Granted Feb 9, 2021·0 cites·23 claims
- 2869US9375423B2Use of aminoindane compounds in treating overactive bladder and interstitial cystitisASANA BIOSCIENCES LLC·Filed 2015·Granted Jun 28, 2016·1 cites·16 claims
- 2969US9371316B2Pyridine derivativesASANA BIOSCIENCES LLC·Filed 2014·Granted Jun 21, 2016·0 cites·18 claims
- 3069US9266873B2Pyridine derivativesASANA BIOSCIENCES LLC·Filed 2014·Granted Feb 23, 2016·0 cites·10 claims
- 3166US2020190095A1Pyrimido-pyridazinone compounds and methods of use thereofASANA BIOSCIENCES LLC·Filed 2020·Application pending·0 cites
- 3265US9533981B2Pyridine derivativesASANA BIOSCIENCES LLC·Filed 2013·Granted Jan 3, 2017·0 cites·21 claims
- 3361US2024082417A1Protein-polymer drug conjugatesASANA BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 3460US2017073339A1Pyridine derivativesASANA BIOSCIENCES LLC·Filed 2016·Application pending·0 cites
- 3559US9115092B2Substituted quinazoline and pyrido-pyrimidine derivativesASANA BIOSCIENCES LLC·Filed 2014·Granted Aug 25, 2015·0 cites·12 claims
- 3658US10226468B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2017·Granted Mar 12, 2019·0 cites·35 claims
- 3758US9757382B2Quinazolines and azaquinazolines as dual inhibitors of RAS/RAF/MEK/ERK and PI3K/AKT/PTEN/mTOR pathwaysASANA BIOSCIENCES LLC·Filed 2016·Granted Sep 12, 2017·0 cites·25 claims
- 3858US2024316046A1Erk1/2 inhibitor combination therapyASANA BIOSCIENCES LLC·Filed 2022·Application pending·0 cites
- 3953US9180115B2CyclohexylaminesASANA BIOSCIENCES LLC·Filed 2014·Granted Nov 10, 2015·0 cites·18 claims
- 4052US2019070182A1Uses of pyrimido-pyridazinones to treat cancerASANA BIOSCIENCES LLC·Filed 2018·Application pending·0 cites
- 4152US2016222014A1Compounds for regulating fak and/or src pathwaysASANA BIOSCIENCES LLC·Filed 2014·Application pending·0 cites
- 4251US2019008868A1Formulations, methods, kits, and dosage forms for treating atopic dermatitis and for improved stability of an active pharmaceutical ingredientASANA BIOSCIENCES LLC·Filed 2018·Application pending·0 cites
- 4349US9199975B2Biaryl imidazole derivatives for regulating CYP17ASANA BIOSCIENCES LLC·Filed 2012·Granted Dec 1, 2015·0 cites·18 claims
- 4449US9145411B2Substituted amino-pyrimidine derivativesASANA BIOSCIENCES LLC·Filed 2013·Granted Sep 29, 2015·0 cites·21 claims
- 4549US2023027072A1Improved methods, kits, compositions and dosing regimens for the use of heterocyclic inhibitors of erk1 and erk2ASANA BIOSCIENCES LLC·Filed 2020·Application pending·0 cites
- 4646US10695296B2Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredientASANA BIOSCIENCES LLC·Filed 2018·Granted Jun 30, 2020·0 cites·28 claims
- 4746US2017319563A1Steroid-free disease managementASANA BIOSCIENCES LLC·Filed 2014·Application pending·0 cites
- 4845US2022000853A1Formulations, methods, kit, and dosage forms for improved stability of an active pharmaceutical ingredientASANA BIOSCIENCES LLC·Filed 2019·Application pending·0 cites
- 4942US2016304617A15t4-targeted immunofusion molecule and methodsASANA BIOSCIENCES LLC·Filed 2014·Application pending·0 cites
- 5041US2016016952A1Substituted amino-pyrimidine derivativesASANA BIOSCIENCES LLC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when ASANA BIOSCIENCES LLC files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →